Page 58 - 2021 White Paper
P. 58
1 White Paper on the Business Environment in China
said he would volunteer to receive the Covid-19 significant systemic side-effects in any of the
vaccine first if people have a "trust deficit" on subjects. We also have permission to immunize
the drug. However, he stressed that frontline subjects who have ¬already had Covid-19 to
health workers, senior citizens and those with see if we can further boost their immunity and
comorbidities should be given the vaccine first p re ve nt t h e m g e t t i n g re - i n fe c te d." Pe t rovs k y
whenever it becomes available. "If there are said he has offered to dose aged care residents
doubts over government or around the scientists at risk of contracting Covid-19 with his vaccine
or over the development of vaccine then to dispel in Victoria, the hardest-hit state in the country.
the doubts I will be the first to get vaccinated," the None of the 40 volunteers in phase one developed
minister said. "However, I personally feel the ones significant side-effects or a fever, and if Covax-19
who need it (vulnerable groups) shall be given the passes phase two, Vaxine would have to enroll
vaccine and I am not among those." Vardhan also up to 50,000 volunteers from around the world
said it was premature to comment on the price for phase three, according to the report (Xinhua,
of the vaccine which was still under trial. "But the Aussie COVID-19).
government of India will assure that the vaccine
will be made available to those who need it the An Australian Covid-19 vaccine under
most, irrespective of their paying capacity," he said development by the University of Queensland
(Xinua, Vaccine Possible). (UQ) and local biotech firm CSL will not progress
to Phase 2/3 trials after returning false positive
Indian Minister of Finance and Corporate HIV test results. Despite eliciting an effective virus
Affairs Nirmala Sitharaman announced a grant response and strong safety profile, a deal for
of over US$120.6 million for the research and the Australian government to purchase over 50
development of Covid-19 vaccine in November million doses of the vaccine had been cancelled.
2020. The announcement came during the spelling UQ and CSL stressed there was no possibility
out of the third stimulus for the revival of economy the vaccine causes HIV infection and that 216
in the wake of the ongoing Covid-19 pandemic. people involved in the trial experienced no
At the time of this writing, three Covid-19 vaccine serious adverse health effects. The issue stems
candidates were in different stages of human from the use of an HIV protein to stabilize UQ's
clinical trials in India. The government also molecular clamp vaccine. Despite posing no risk
approved over US$2 billion financial outlay to to health, the presence of the protein prompts
incentivize the global and domestic players to an antibody response which is detectable in
engage in high-value production of pharmaceutical HIV tests. However, due to the implications of
drugs (Xinhua, India’s Finance). delivering the vaccine to the broader populations
and potential interference with existing HIV testing
Oceania procedures, CSL and the Australian government
agreed vaccine development would not proceed
A Covid-19 candidate vaccine developed in to Phase 2/3 trials. Chief Scientific Officer for CSL
South Australia (SA) cleared the first phase of Dr. Andrew Nash said the outcome "highlights
testing in July 2020. The vaccine developed by the risk of failure associated with early vaccine
Nikolai Petrovsky from Flinders University was development." CSL will continue with plans to
the first Australian candidate to pass phase one manufacture approximately 30 million doses
trials after it was found to be safe and generated of the Oxford/AstraZeneca vaccine candidate
an immune response in human subjects. Dubbed with first doses planned for release in Australia
"Cova x- 1 9 ," t h e va cc i n e wa s a d m i n i s te re d to in early 2021. Following the failure of the UQ
40 volunteers in the first phase of trials. "We vaccine, the Australian government revealed it
have confirmed that the Covax-19 vaccine can would commission the manufacture of additional
induce ¬appropriate antibody responses in 20 million doses of the Oxford/AstraZeneca and
human subjects," said Petrovsky, the founder of increase access to the US Novavax vaccine to
biotechnology company Vaxine. We now have around 50 million doses. Australian Prime Minister
preliminary safety data showing there were no Scott Morrison said it was no surprise that not
all vaccine candidates made it through the trial
58
said he would volunteer to receive the Covid-19 significant systemic side-effects in any of the
vaccine first if people have a "trust deficit" on subjects. We also have permission to immunize
the drug. However, he stressed that frontline subjects who have ¬already had Covid-19 to
health workers, senior citizens and those with see if we can further boost their immunity and
comorbidities should be given the vaccine first p re ve nt t h e m g e t t i n g re - i n fe c te d." Pe t rovs k y
whenever it becomes available. "If there are said he has offered to dose aged care residents
doubts over government or around the scientists at risk of contracting Covid-19 with his vaccine
or over the development of vaccine then to dispel in Victoria, the hardest-hit state in the country.
the doubts I will be the first to get vaccinated," the None of the 40 volunteers in phase one developed
minister said. "However, I personally feel the ones significant side-effects or a fever, and if Covax-19
who need it (vulnerable groups) shall be given the passes phase two, Vaxine would have to enroll
vaccine and I am not among those." Vardhan also up to 50,000 volunteers from around the world
said it was premature to comment on the price for phase three, according to the report (Xinhua,
of the vaccine which was still under trial. "But the Aussie COVID-19).
government of India will assure that the vaccine
will be made available to those who need it the An Australian Covid-19 vaccine under
most, irrespective of their paying capacity," he said development by the University of Queensland
(Xinua, Vaccine Possible). (UQ) and local biotech firm CSL will not progress
to Phase 2/3 trials after returning false positive
Indian Minister of Finance and Corporate HIV test results. Despite eliciting an effective virus
Affairs Nirmala Sitharaman announced a grant response and strong safety profile, a deal for
of over US$120.6 million for the research and the Australian government to purchase over 50
development of Covid-19 vaccine in November million doses of the vaccine had been cancelled.
2020. The announcement came during the spelling UQ and CSL stressed there was no possibility
out of the third stimulus for the revival of economy the vaccine causes HIV infection and that 216
in the wake of the ongoing Covid-19 pandemic. people involved in the trial experienced no
At the time of this writing, three Covid-19 vaccine serious adverse health effects. The issue stems
candidates were in different stages of human from the use of an HIV protein to stabilize UQ's
clinical trials in India. The government also molecular clamp vaccine. Despite posing no risk
approved over US$2 billion financial outlay to to health, the presence of the protein prompts
incentivize the global and domestic players to an antibody response which is detectable in
engage in high-value production of pharmaceutical HIV tests. However, due to the implications of
drugs (Xinhua, India’s Finance). delivering the vaccine to the broader populations
and potential interference with existing HIV testing
Oceania procedures, CSL and the Australian government
agreed vaccine development would not proceed
A Covid-19 candidate vaccine developed in to Phase 2/3 trials. Chief Scientific Officer for CSL
South Australia (SA) cleared the first phase of Dr. Andrew Nash said the outcome "highlights
testing in July 2020. The vaccine developed by the risk of failure associated with early vaccine
Nikolai Petrovsky from Flinders University was development." CSL will continue with plans to
the first Australian candidate to pass phase one manufacture approximately 30 million doses
trials after it was found to be safe and generated of the Oxford/AstraZeneca vaccine candidate
an immune response in human subjects. Dubbed with first doses planned for release in Australia
"Cova x- 1 9 ," t h e va cc i n e wa s a d m i n i s te re d to in early 2021. Following the failure of the UQ
40 volunteers in the first phase of trials. "We vaccine, the Australian government revealed it
have confirmed that the Covax-19 vaccine can would commission the manufacture of additional
induce ¬appropriate antibody responses in 20 million doses of the Oxford/AstraZeneca and
human subjects," said Petrovsky, the founder of increase access to the US Novavax vaccine to
biotechnology company Vaxine. We now have around 50 million doses. Australian Prime Minister
preliminary safety data showing there were no Scott Morrison said it was no surprise that not
all vaccine candidates made it through the trial
58
